Is It Time for China to Prioritize Pan-genotypic Regimens for Treating Patients with Hepatitis C?

Overview

Journal Cost Eff Resour Alloc

Publisher Biomed Central

Date 2024 Feb 6

PMID 38321475

Authors

Yusi Tu

Xiangyan Tang

Dachuang Zhou

Hanqiao Shao

Leyi Liang

Wenxi Tang

Affiliations

Soon will be listed here.

Abstract

Introduction: The treatment of hepatitis C has entered the pan-genotypic era, but the effectiveness is not good for the genotype 3b patients who have a large proportion in China. The guidelines for hepatitis C recommend the use of gene-specific regimens when the regional 3b prevalence rate greater than 5%. This study is to explore rationality of this proportion and the cost-effectiveness to implement pan-genotypic regimens in China.

Methods: A decision Markov model was developed from the health system perspective to evaluate the effectiveness and cost-effectiveness between pan-genotypic and gene-specific treatment regimens for hepatitis C patients. Additionally, we set a regional genotype 3b patient proportion of 0-100% to explore at which proportion it is necessary to perform genotype identification and typing therapy on patients. Model parameters were derived from published literature and public databases. Effectiveness was measured by cured patient numbers, newly diagnosed cases of decompensated cirrhosis, hepatocellular carcinoma, need for liver transplantation, and quality-adjusted life years (QALYs). Cost-effectiveness outcomes included costs and the incremental cost-effectiveness ratio (ICER). The 1-3 times 2022 Chinese per capita gross domestic product was used as the willingness-to-pay threshold. One-way and probabilistic sensitivity analyses were performed to assess the uncertainty of the model parameters.

Results: Compared with gene-specific regimens, pan-genotypic regimens resulted in an additional 0.13 QALYs and an incremental cost of $165, the ICER was $1,268/QALY. From the view of efficacy, the pan-genotypic regimens cured 5,868 more people per 100,000 patients than gene-specific regimens, avoiding 86.5% of DC cases, 64.6% of HCC cases, and 78.2% of liver transplant needs. Identifying 3b patients before treatment was definitely cost-effectiveness when their prevalence was 12% or higher. The results remained robust in sensitivity analyses.

Conclusions: In China, the prioritized recommendation of pan-genotypic therapeutics proves to be both cost-effective and efficacious. But, in regions where the prevalence of genotype 3b exceeds 12%, it is necessary to identify them to provision of more suitable therapies.

References

Tao J, Liang J, Zhang H, Pei L, Qian H, Chambers M . The Molecular Epidemiological Study of HCV Subtypes among Intravenous Drug Users and Non-Injection Drug Users in China. PLoS One. 2015; 10(10):e0140263. PMC: 4605846. DOI: 10.1371/journal.pone.0140263. View

Younossi Z, Singer M, Mir H, Henry L, Hunt S . Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol. 2013; 60(3):530-7. DOI: 10.1016/j.jhep.2013.11.009. View

Wang S, Wang J, Chen J, Giri R, Chen M . Natural history of liver cirrhosis in south China based on a large cohort study in one center: a follow-up study for up to 5 years in 920 patients. Chin Med J (Engl). 2012; 125(12):2157-62. View

Zhou H, Cao J, Shi H, Naidoo N, Semba S, Wang P . Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China. Front Public Health. 2021; 9:779215. PMC: 8695807. DOI: 10.3389/fpubh.2021.779215. View

Chhatwal J, He T, Lopez-Olivo M . Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals. Pharmacoeconomics. 2016; 34(6):551-67. DOI: 10.1007/s40273-015-0373-9. View

Bourliere M, Gordon S, Flamm S, Cooper C, Ramji A, Tong M . Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection. N Engl J Med. 2017; 376(22):2134-2146. DOI: 10.1056/NEJMoa1613512. View

Chang L, Chang H, Chen P, Chen C, Tsai K, Yean K . Factors Associated with the Refusal of Direct-Acting Antiviral Agents for the Treatment of Hepatitis C in Taiwan. Medicina (Kaunas). 2022; 58(4). PMC: 9031294. DOI: 10.3390/medicina58040521. View

Schmitt A, Gunther R, Mauss S, Boeker K, Buggisch P, Hillenbrand H . Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R). Z Gastroenterol. 2020; 58(4):341-351. DOI: 10.1055/a-1068-3056. View

Sarin S, Kumar M, Eslam M, George J, Al Mahtab M, Akbar S . Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2019; 5(2):167-228. PMC: 7164809. DOI: 10.1016/S2468-1253(19)30342-5. View

10.

Lee M, Yang H, Yuan Y, LItalien G, Chen C . Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol. 2014; 20(28):9270-80. PMC: 4110557. DOI: 10.3748/wjg.v20.i28.9270. View

11.

Wu J, Zhou Y, Fu X, Deng M, Zheng Y, Tian G . The Burden of Chronic Hepatitis C in China From 2004 to 2050: An Individual-Based Modeling Study. Hepatology. 2018; 69(4):1442-1452. DOI: 10.1002/hep.30476. View

12.

Stanciu C, Muzica C, Girleanu I, Cojocariu C, Sfarti C, Singeap A . An update on direct antiviral agents for the treatment of hepatitis C. Expert Opin Pharmacother. 2021; 22(13):1729-1741. DOI: 10.1080/14656566.2021.1921737. View

13.

Chen P, Jin M, Cao Y, Li H . Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C. Appl Health Econ Health Policy. 2020; 19(3):371-387. DOI: 10.1007/s40258-020-00623-3. View

14.

Xu Q, Zhang W, Ma Y, He C, Zhang L, Abulitifu Y . [Twelve-week of sofosbuvir/velpatasvir therapeutic regimen for chronic hepatitis C patients in northwest region of China: a real-world multicenter clinical study]. Zhonghua Gan Zang Bing Za Zhi. 2021; 29(11):1046-1052. DOI: 10.3760/cma.j.cn501113-20201010-00548. View

15.

Thein H, Yi Q, Dore G, Krahn M . Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008; 48(2):418-31. DOI: 10.1002/hep.22375. View

16.

Lo C, Huang C, Cheng P, Tseng K, Chen C, Kuo H . Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan. J Formos Med Assoc. 2022; 121(8):1567-1578. DOI: 10.1016/j.jfma.2022.01.012. View

17.

Rao H, Wei L, Lopez-Talavera J, Shang J, Chen H, Li J . Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2013; 29(3):545-53. PMC: 4272577. DOI: 10.1111/jgh.12398. View

18.

Chen G, Wei L, Chen J, Duan Z, Dou X, Xie Q . Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data. PLoS One. 2016; 11(6):e0155934. PMC: 4898683. DOI: 10.1371/journal.pone.0155934. View

19.

Bajis S, Applegate T, Grebely J, Matthews G, Dore G . Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic. J Infect Dis. 2020; 222(Suppl 9):S758-S772. DOI: 10.1093/infdis/jiaa366. View

20.

Zhao Z, Chu M, Guo Y, Yang S, Abudurusuli G, Frutos R . Feasibility of Hepatitis C Elimination in China: From Epidemiology, Natural History, and Intervention Perspectives. Front Microbiol. 2022; 13:884598. PMC: 9201439. DOI: 10.3389/fmicb.2022.884598. View